TD Cowen raised the firm’s price target on NeoGenomics (NEO) to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics’s new product launches, saying MolDX reimbursement remains the “final gate” for a 2026 ramp.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Buy Rating: Strategic Product Launches and Management Changes Drive Growth Potential
- NeoGenomics price target raised to $11 from $6.50 at Stephens
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz
- NeoGenomics’ Legal Victory and Market Potential Boosts Buy Rating
- NeoGenomics announces court ruling in its favor in lawsuit against Natera